Page 112 - Read Online

Page 73 Oboma et al. J Transl Genet Genom. 2025;9:62-75 https://dx.doi.org/10.20517/jtgg.2024.74

Drafting, revising and editing, proofreading: Ekpenyong B
Data extraction, article screening, and literature search: Charles M. A, Kenneth E. M

Availability of data and materials
Not applicable.

Financial support and sponsorship
Not applicable.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2025.

REFERENCES
1. Key statistics for prostate cancer. 2024. Available from: https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html
[Last accessed on 20 Mar 2025].
2. Rawla P. Epidemiology of prostate cancer. World J Oncol. 2019;10:63-89. DOI PubMed PMC
3. Wang Y, Li X, You Z. Comparative analysis of the incidence, diagnosis and treatment of prostate cancer between China and the
United States. Serican J Med. 2025:2. DOI
4. Prostate Cancer Foundation. 2022. Available from: https://www.pcf.org [Last accessed on 20 Mar 2025].
5. Chen T, Wang M, Chen Y, Liu Y. Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors. Cancer Cell
Int. 2024;24:133. DOI PubMed PMC
6. Stefanoudakis D, Kathuria-Prakash N, Sun AW, et al. The potential revolution of cancer treatment with CRISPR technology. Cancers.
2023;15:1813. DOI PubMed PMC
7. Li YR, Halladay T, Yang L. Immune evasion in cell-based immunotherapy: unraveling challenges and novel strategies. J Biomed Sci.
2024;31:5. DOI PubMed PMC
8. Logotheti S, Papadaki E, Zolota V, et al. Lineage plasticity and stemness phenotypes in prostate cancer: harnessing the power of
integrated “omics” approaches to explore measurable metrics. Cancers. 2023;15:4357. DOI PubMed PMC
9. Chen L, Li Q, Wang Y, Zhang Y, Ma X. Comparison on efficacy of radical prostatectomy versus external beam radiotherapy for the
treatment of localized prostate cancer. Oncotarget. 2017;8:79854-63. DOI PubMed PMC
10. Desai K, McManus JM, Sharifi N. Hormonal therapy for prostate cancer. Endocr Rev. 2021;42:354-73. DOI PubMed PMC
11. Corn PG, Heath EI, Zurita A, et al. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate
cancers: a randomised, open-label, phase 1-2 trial. Lancet Oncol. 2019;20:1432-43. DOI PubMed PMC
12. Michaelson MD, Cotter SE, Gargollo PC, Zietman AL, Dahl DM, Smith MR. Management of complications of prostate cancer
treatment. CA Cancer J Clin. 2008;58:196-213. DOI PubMed PMC
13. Talkar SS, Patravale VB. Gene therapy for prostate cancer: a review. Endocr Metab Immune Disord Drug Targets. 2021;21:385-96.
DOI PubMed
14. Gudenkauf LM, Gray S, Gonzalez BD, Sachdeva A, Autio K. Balancing hormone therapy: mitigating adverse effects of androgen-
deprivation therapy and exploring alternatives in prostate cancer management. Am Soc Clin Oncol Educ Book. 2024;44:e433126. DOI
PubMed
15. Dogbey DM, Torres VES, Fajemisin E, et al. Technological advances in the use of viral and non-viral vectors for delivering genetic
and non-genetic cargos for cancer therapy. Drug Deliv Transl Res. 2023;13:2719-38. DOI PubMed PMC
16. Eade TN, Hanlon AL, Horwitz EM, Buyyounouski MK, Hanks GE, Pollack A. What dose of external-beam radiation is high enough
for prostate cancer? Int J Radiat Oncol Biol Phys. 2007;68:682-9. DOI PubMed PMC
17. Osuchowski M, Osuchowski F, Latos W, Kawczyk-Krupka A. The use of upconversion nanoparticles in prostate cancer photodynamic
therapy. Life. 2021;11:360. DOI PubMed PMC